Notably, in PD-L1-positive recurrent/metastatic HNSCC, adding AK117 to ivonescimab improved the ORR from 40% to 65% and prolonged mPFS to 7.1 months, supporting the pivotal phase III trial (AK117-302) [165]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.